MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

51.38
-1.82
-3.42%
After Hours: 51.55 +0.17 +0.33% 17:47 01/21 EST
OPEN
53.01
PREV CLOSE
53.20
HIGH
53.53
LOW
50.68
VOLUME
482.35K
TURNOVER
--
52 WEEK HIGH
99.00
52 WEEK LOW
39.35
MARKET CAP
2.41B
P/E (TTM)
-60.6111
1D
5D
1M
3M
1Y
5Y
Analyst Ratings For Glaukos
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the last quarter:
Benzinga · 3d ago
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Benzinga · 01/12 17:36
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 01/12 13:30
Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile
Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) 
Benzinga · 01/12 10:47
BRIEF-Glaukos Announces First Patient Enrolled In Phase 2 Clinical Trial For Dry Eye Disease
reuters.com · 01/11 22:01
Glaukos ' iDose TR Demonstrates Sustained IOP Reduction And Favorable Safety Profile Over 36 Months In Phase 2b Study; Says ~70% Of Subjects Were Well-Controlled
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that
Benzinga · 01/11 21:12
Glaukos Announces First Patient Enrolled In Phase 2 Clinical Trial For Presbyopia
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has
Benzinga · 01/11 21:12
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
SAN CLEMENTE, Calif., January 11, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it ...
Business Wire · 01/11 21:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GKOS. Analyze the recent business situations of Glaukos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

10.00%Strong Buy
0.00%Buy
70.00%Hold
20.00%Under-perform
0.00%Sell
Analyst Price Target
The average GKOS stock price target is 52.57 with a high estimate of 68.00 and a low estimate of 40.00.
High68.00
Average52.57
Low40.00
Current 51.38
EPS
Actual
Estimate
-0.30-0.22-0.15-0.07
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 301
Institutional Holdings: 58.14M
% Owned: 123.99%
Shares Outstanding: 46.89M
TypeInstitutionsShares
Increased
84
5.39M
New
33
2.00M
Decreased
52
10.10M
Sold Out
43
1.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.93%
Healthcare Equipment & Supplies
-1.50%
Key Executives
Chairman/President/Chief Executive Officer/Director
Thomas Burns
Chief Financial Officer/Senior Vice President
Joseph Gilliam
Chief Operating Officer
Chris Calcaterra
Lead Director/Independent Director
Mark Foley
Independent Director
David Hoffmeister
Independent Director
Gilbert Kliman
Independent Director
Marc Stapley
Independent Director
Denice Torres
Independent Director
Aimee Weisner
Independent Director
Leana Wen
No Data
About GKOS
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to the traditional glaucoma treatment paradigm. It offers bio-activated pharmaceutical therapy for the treatment of corneal disorder and keratoconus. It is also developing a pipeline of surgical devices, sustained pharmaceutical therapies, implantable biosensors intended to treat glaucoma progression, corneal disorders such as keratoconus, dry eye, refractive vision correction, retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.